Dopo l'orario di chiusura: 70.20 -0.38 -0.54%

Biomarin Pharmaceutical Inc (BMRN)

Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie

Biomarin Pharmaceutical Inc (BMRN)

Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie

Dimensional Fund Advisors LP Boosts Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish - Yahoo Finance

BIIB: 3 Biotech Stocks Wall Street Predicts Will Skyrocket - StockNews.com

BioMarin’s Voxzogo stock outlook intact as competition rises, says Goldman Sachs - Investing.com

BioMarin’s Voxzogo stock outlook intact as competition rises, says Goldman Sachs - Investing.com India

Troluce Capital Advisors LLC Takes Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat

BioMarin stock touches 52-week low at $68.8 amid market challenges - Investing.com Australia

Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace

Examining the Potential Price Growth of Biomarin Pharmaceutical Inc. (BMRN) - Knox Daily

Biomarin Pharmaceutical Options Trading: A Deep Dive into Market Sentiment - Benzinga

BioMarin Pharmaceutical reaffirms long-term outlook - MSN

BioMarin Pharmaceutical (NASDAQ:BMRN) Hits New 12-Month Low at $68.73 - Defense World

BioMarin stock touches 52-week low at $68.8 amid market challenges - Investing.com

BioMarin stock touches 52-week low at $68.8 amid market challenges - Investing.com UK

Australis mortgages 15 Chilean salmon farms to BioMar, Vitapro - Undercurrent News

BioMarin Pharmaceutical Projects Strong Growth Through 2034 - TipRanks

Biomarin Pharmaceutical Inc Reaffirming Its Long-Term Financial Guidance And Outlook That It Presented During Investor Day - XM

BioMarin Pharmaceutical (NASDAQ:BMRN) Issues FY 2024 Earnings Guidance - Defense World

BioMarin Pharmaceutical (NASDAQ:BMRN) Issues FY 2024 Earnings Guidance - MarketBeat

Poor planning, patient reluctance, and payer problems hurting gene therapy space - BioProcess Insider

Renaissance Technologies LLC Decreases Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat

New 4-Star Stocks - Morningstar

Daily Market Movement: Biomarin Pharmaceutical Inc. (BMRN) Sees a -1.01 Decrease, Closing at 70.69 - The Dwinnex

BioMar sees farm partnerships, tech as future of shrimp feed M&A - Undercurrent News

Canada Pension Plan Investment Board Has $19.80 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat

Canada Pension Plan Investment Board Has $19.80 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World

Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? - Benzinga

Ameritas Investment Partners Inc. Buys Shares of 40,387 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat

BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly - Simply Wall St

BioMarin (BMRN): Strong Results and ROCTAVIAN Progress Make It a Mid-Cap Growth Gem - Insider Monkey

BioMarin (BMRN): Strong Results and ROCTAVIAN Progress Make It a Mid-Cap Growth Gem - Yahoo Finance

20,167 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Bought by Federated Hermes Inc. - MarketBeat

Simplify Asset Management Inc. Takes $417,000 Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World

Amalgamated Bank Grows Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Expected to Earn Q1 2025 Earnings of $0.59 Per Share - MarketBeat

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by Meiji Yasuda Life Insurance Co - Defense World

Mutual of America Capital Management LLC Purchases Shares of 108,713 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World

Citi maintains Neutral on BioMarin with $93 target - Investing.com India

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by E Fund Management Co. Ltd. - MarketBeat

Citi maintains Neutral on BioMarin with $93 target By Investing.com - Investing.com Canada

BioMarin Pharmaceutical (NASDAQ:BMRN) PT Lowered to $90.00 - Defense World

Citi maintains Neutral on BioMarin with $93 target - Investing.com

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Short Interest Update - Defense World

16 Best Mid Cap Growth Stocks To Buy Now - Insider Monkey

Texas Permanent School Fund Corp Invests $2.19 Million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World

BioMarin announces results from CANOPY clinical program evaluating VOXZOGO - TipRanks

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meetin - StockTitan

Bokf Na Acquires Shares of 375 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World

Positive Ascendis data threatens BioMarin's lead in achondroplasia - The Pharma Letter

BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $87.00 Price Target at Stifel Nicolaus - Defense World

BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Cut to $115.00 by Analysts at Bank of America - Defense World

Texas Permanent School Fund Corp Buys New Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat

(BMRN) Trading Advice - Stock Traders Daily

Ascendis Challenges BioMarin, But Market Response Seems Excessive (NASDAQ:BMRN) - Seeking Alpha

BioMarin shares target cut, retains buy rating on Ascendis trial results - Investing.com

BioMarin Pharmaceutical (NASDAQ:BMRN) PT Lowered to $78.00 - MarketBeat

BioMarin Pharmaceutical: A Volatile But Growing Trajectory (NASDAQ:BMRN) - Seeking Alpha

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Short Interest Update - MarketBeat

Ascendis trial data piles pressure on BioMarin - BioPharma Dive

Baird maintains Neutral rating on BioMarin stock, cites competition concerns - Investing.com India

RBC Capital reduces BioMarin stock price target, keeps Sector Perform rating - Investing.com India

BioMarin: Potential Voxzogo Competition Lowers Our Valuation, but Shares Look Attractive - Morningstar

Healthy Upside Potential: Biomarin Pharmaceutical Inc. (BMRN) - SETE News

BioMarin's Rare Disease Portfolio Supports a Narrow Economic Moat - Morningstar

BioMarin price target lowered to $78 from $95 at Scotiabank - TipRanks

Ascendis' dwarfism drug accelerates growth in phase 3, teeing up challenge to BioMarin - Fierce Biotech

Scotiabank lowers outlook for BioMarin shares, highlights competitive risks to Voxzogo franchise - Investing.com India

Tuesday's Stocks on Sale: AVAV, BMRN, QRVO and ARM - Baystreet.ca

Balance Sheet Dive: Biomarin Pharmaceutical Inc. (BMRN)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

BioMarin price target lowered to $90 from $118 at Truist - TipRanks

BioMarin price target lowered to $85 from $100 at RBC Capital - TipRanks

BioMarin price target lowered to $90 from $116 at Bernstein - TipRanks

BioMarin price target lowered to $90 from $115 at Wells Fargo - TipRanks

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by Acadian Asset Management LLC - Defense World

Primecap Management Co. CA Boosts Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat

Barclays maintains BioMarin at Overweight with $110 target - Investing.com

Ascendis’ TransCon Positioned To Take On BioMarin’s Voxzogo - Scrip

Simile a BMRN